REFERENCES
1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50.
2. Fracanzani AL, Tiraboschi S, Pisano G, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 2016;246:208-13.
4. Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.
5. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med 2014;371:1131-41.
6. Adiels M, Olofsson SO, Taskinen MR, Borén J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006;17:238-46.
7. Adiels M, Taskinen MR, Borén J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008;8:60-4.
8. Björnson E, Adiels M, Taskinen MR, Borén J. Kinetics of plasma triglycerides in abdominal obesity. Curr Opin Lipidol 2017;28:11-8.
9. Bellosta S, Rossi C, Alieva AS, Catapano AL, Corsini A, Baragetti A. Cholesterol lowering biotechnological strategies: from monoclonal antibodies to antisense therapies. A pre-clinical perspective review. Cardiovasc Drugs Ther 2022; doi: 10.1007/s10557-021-07293-w.
10. Baragetti A, Grejtakova D, Casula M, et al. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: facts and gaps. Pharmacol Res 2018;130:1-11.
11. Nordestgaard BG. A Test in context: lipid profile, fasting versus nonfasting. J Am Coll Cardiol 2017;70:1637-46.
12. Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb 2017;24:95-109.
13. Berry SE, Valdes AM, Drew DA, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med 2020;26:964-73.
14. Sharrett AR, Heiss G, Chambless LE, et al. Metabolic and lifestyle determinants of postprandial lipemia differ from those of fasting triglycerides: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol 2001;21:275-81.
15. Dubois C, Beaumier G, Juhel C, et al. Effects of graded amounts (0-50 g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am J Clin Nutr 1998;67:31-8.
16. Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin 2014;30:1489-503.
17. FoodData Central [Internet]. Available from: https://fdc.nal.usda.gov/ [Last accessed on 27 Jun 2022].
18. BDA | Food Composition Database for Epidemiological Studies in Italy [Internet]. Available from: http://www.bda-ieo.it/wordpress/en/ [Last accessed on 27 Jun 2022].
19. Sun L, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat Rev Gastroenterol Hepatol 2021;18:335-347.
20. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. lancet Diabetes Endocrinol 2014;2:655-666.
21. Johansen CT, Hegele RA. Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol 2011;22:247-253.
22. Hansen SEJ, Madsen CM, Varbo A, Nordestgaard BG. Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population. Clin Chem 2019;65:321-332.
23. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-188.
24. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021;42:4791-4806.
25. Tada H, Nohara A, Inazu A, Mabuchi H, Kawashiri M aki. Remnant lipoproteins and atherosclerotic cardiovascular disease. Clin Chim Acta 2019;490:1-5.
26. Salinas CAA, Chapman MJ. Remnant lipoproteins: are they equal to or more atherogenic than LDL? Curr Opin Lipidol 2020;31:132-139.
27. Nakajima K, Nakano T, Tokita Y, et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011;412:1306-1318.
28. Sniderman AD. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J Clin Lipidol 2008;2:36-42.
29. Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 2017;318:947-956.
30. Bini S, D’Erasmo L, Di Costanzo A, Minicocci I, Pecce V, Arca M. The interplay between angiopoietin-Like proteins and adipose tissue: another piece of the relationship between adiposopathy and cardiometabolic diseases? Int J Mol Sci 2021;22:1-16.
31. Minicocci I, Santini S, Cantisani V, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res 2013;54:3481-3490.
32. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554.
33. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397.
34. Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res 2021;51:1115-1128.
36. Moreton JR. Physical state of lipids and foreign substances producing atherosclerosis. Science 1948;107:371-373.
37. Schwartz EA, Reaven PD. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis. Biochim Biophys Acta 2012;1821:858-866.
38. Higgins LJ, Rutledge JC. Inflammation associated with the postprandial lipolysis of triglyceride-rich lipoproteins by lipoprotein lipase. Curr Atheroscler Rep 2009;11:199-205.
39. Ting HJ, Stice JP, Schaff UY, et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-α. Circ Res 2007;100:381-390.
40. Zewinger S, Reiser J, Jankowski V, et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol 2020;21:30-41.
41. Doi H, Kugiyama K, Oka H, et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000;102:670-676.
42. De Sousa JC, Soria C, Ayrault-Jarrier M, et al. Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol 1988;41:940-944.
43. Mattavelli E, Catapano AL, Baragetti A. Molecular immune-inflammatory connections between dietary fats and atherosclerotic cardiovascular disease: which translation into clinics? Nutrients 2021:13.
44. Ajuwon K, Spurlock M. Palmitate activates the NF-kappaB transcription factor and induces IL-6 and TNFalpha expression in 3T3-L1 adipocytes. J Nutr 2005;135:1841-1846.
45. Lee J, Zhao L, Youn H, et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004;279:16971-16979.
46. Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci 2021;78:1233-1261.
47. Lee JY, Plakidas A, Lee WH, et al. Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003;44:479-486.
48. Veglia F, Tyurin VA, Blasi M, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 2019;569:73-78.
49. Zheng S, Ma M, Li Z, et al. Posttreatment of Maresin1 Inhibits NLRP3 inflammasome activation via promotion of NLRP3 ubiquitination. FASEB J 2020;34:11944-11956.
50. Viola JR, Lemnitzer P, Jansen Y, et al. Resolving lipid mediators maresin 1 and resolvin D2 prevent atheroprogression in mice. Circ Res 2016;119:1030-1038.
51. Adam AC, Lie KK, Moren M, Skjærven KH. High dietary arachidonic acid levels induce changes in complex lipids and immune-related eicosanoids and increase levels of oxidised metabolites in zebrafish (Danio rerio). Br J Nutr 2017;117:1075-1085.
52. Holladay CS, Wright RM, Spangelo BL. Arachidonic acid stimulates interleukin-6 release from rat peritoneal macrophages in vitro: evidence for a prostacyclin-dependent mechanism. Prostaglandins Leukot Essent Fatty Acids 1993;49:915-922.
53. Shen Z, Ma Y, Ji Z, et al. Arachidonic acid induces macrophage cell cycle arrest through the JNK signaling pathway. Lipids Health Dis 2018;17:26.
54. Wellenstein MD, de Visser KE. Fatty acids corrupt neutrophils in cancer. Cancer Cell 2019;35:827-829.
55. Alsina-Sanchis E, Mülfarth R, Moll I, Mogler C, Rodriguez-Vita J, Fischer A. Intraperitoneal oil application causes local inflammation with depletion of resident peritoneal macrophages. Mol Cancer Res 2021;19:288-300.
56. Christ A, Lauterbach M, Latz E. Western diet and the immune system: an inflammatory connection. Immunity 2019;51:794-811.
57. Astrup A, Magkos F, Bier DM, et al. Saturated fats and health: a reassessment and proposal for food-based recommendations: JACC state-of-the-art review. J Am Coll ;76:844-857.
58. Sheedy FJ, Grebe A, Rayner KJ, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 2013;14:812-820.
59. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015;15:104-116.
60. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-1361.
61. Bekkering S, Quintin J, Joosten LAB, Van Der Meer JWM, Netea MG, Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler Thromb Vasc Biol 2014;34:1731-1738.
62. Christ A, Günther P, Lauterbach MAR, et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell 2018;172:162-175.e14.
63. Toutouzas K, Skoumas J, Koutagiar I, et al. Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia. J Clin Lipidol 2018;12:33-43.
64. Bernelot Moens SJ, Verweij SL, Schnitzler JG, et al. Remnant cholesterol elicits arterial wall inflammation and a multilevel cellular immune response in humans. Arterioscler Thromb Vasc Biol 2017;37:969-975.
65. Raposeiras-Roubin S, Rosselló X, Oliva B, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021;77:3031-3041.
66. Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes 2020;69:508-516.
67. Borén J, John Chapman M, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313-2330.
68. Mahely R, Innerarity T, Rall S, Weisgraber K. Lipoproteins of special significance in atherosclerosis: insights provided by studies of type III hyperlipoproteinemia. Ann N Y Acad Sci 1985;454:209-221.
69. Norata GD, Grigore L, Raselli S, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007;193:321-327.
70. Schnitzler JG, Moens SJB, Tiessens F, et al. Nile red quantifier: a novel and quantitative tool to study lipid accumulation in patient-derived circulating monocytes using confocal microscopy. J Lipid Res 2017;58:2210-2219.
71. Klop B, Proctor SD, Mamo JC, Botham KM, Castro Cabezas M. Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases. Int J Vasc Med 2012;2012:1-11.
72. Aboumsallem JP, Muthuramu I, Mishra M, De Geest B. Cholesterol-lowering gene therapy prevents heart failure with preserved ejection fraction in obese type 2 diabetic mice. Int J Mol Sci 2019;20:2222.
73. Pourcet B, Staels B. Alternative macrophages in atherosclerosis: not always protective! J Clin Invest 2018;128:910-912.
74. Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma apolipoprotein E levels and risk of dementia: a Mendelian randomization study of 106,562 individuals. Alzheimers Dement 2018;14:71-80.
75. Bonacina F, Coe D, Wang G, et al. Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. Nat Commun 2018;9:3083.
76. Liberale L, Dallegri F, Montecucco F, Carbone F. Pathophysiological relevance of macrophage subsets in atherogenesis. Thromb Haemost 2017;117:7-18.
77. Westerterp M, Murphy AJ, Wang M, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res 2013;112:1456-65.
78. Baragetti A, Bonacina F, Catapano AL, Norata GD. Effect of lipids and lipoproteins on hematopoietic cell metabolism and commitment in atherosclerosis. Immunometabolism 2021:3.
79. Kaplan R, Zhang T, Hernandez M, et al. Regulation of the angiopoietin-like protein 3 gene by LXR. J Lipid Res 2003;44:136-143.
80. Zheng J, Huynh HD, Umikawa M, Silvany R, Zhang CC. Angiopoietin-like protein 3 supports the activity of hematopoietic stem cells in the bone marrow niche. Blood 2011;117:470-479.
81. Chadwick AC, Evitt NH, Lv W, Musunuru K. Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3. Circulation 2018;137:975-977.
82. Zhang CC, Kaba M, Ge G, et al. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med 2006;12:240-245.
83. Collaboration CTT (CTT). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
84. Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017;71:17-32.
85. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-1292.
86. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77C-81C.
87. Kaplan DE, Serper MA, Mehta R, et al. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology 2019;156:1693-1706.e12.
88. Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017;15:1521-1530.
89. Thomson MJ, Serper M, Khungar V, et al. Prevalence and factors associated with statin use among patients with nonalcoholic fatty liver disease in the TARGET-NASH study. Clin Gastroenterol Hepatol 2022;20:458-460.
90. Torres-Peña JD, Martín-Piedra L, Fuentes-Jiménez F. Statins in non-alcoholic steatohepatitis. Front Cardiovasc Med 2021;8:777131.
91. Shepherd J, Caslake MJ, Lorimer AR, Vallance BD, Packard CJ. Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 1985;5:162-168.
92. Ginsberg HN. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. Am J Med 1987;83:66-70.
93. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 2015;62:720-733.
94. Kooistra T, Verschuren L, De Vries-Van Der Weij J, et al. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 2006;26:2322-30.
95. Okopień B, Krysiak R, Herman ZS. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006;91:1770-1778.
96. Krysiak R, Gdula-Dymek A, Okopieñ B. Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol Rep 2013;65:1311-1316.
97. Ginsberg H, Elam M, Lovato L, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574.
98. Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-498.
99. Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092.
100. Seko Y, Yamaguchi K, Umemura A, et al. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: a single-arm, pilot study. Hepatol Res 2020;50:1328-1336.
101. Hatanaka T, Kakizaki S, Saito N, et al. Impact of pemafibrate in patients with hypertriglyceridemia and metabolic dysfunction-associated fatty liver disease pathologically diagnosed with non-alcoholic steatohepatitis: a retrospective, single-arm study. Intern Med 2021;60:2167-2174.
102. Phase 3 CV outcomes study with pemafibrate stopped early - PACE-CME [Internet]. Available from: https://pace-cme.org/2022/04/11/phase-3-cv-outcomes-study-with-pemafibrate-stopped-early/ [Last accessed on 27 Jun 2022].
103. Shearer GC, Savinova O V, Harris WS. Fish oil -- how does it reduce plasma triglycerides? Biochim Biophys Acta 2012;1821:843-851.
104. Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis 2017;16:149.
105. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22.
106. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 2014;371:2200-06.
107. Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 2019;381:531-542.
108. Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation 2019;140:470-486.
109. Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J 2020;41:3936-3945.
110. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. Drug Ther Bull 2016;54:101.
111. Nogueira JP, Maraninchi M, Béliard S, et al. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Arterioscler Thromb Vasc Biol 2012;32:1039-1044.
112. Parlevliet ET, Wang Y, Geerling JJ, et al. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One 2012;7:e49152.
113. Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 2021;11:1-13.
114. Geerling JJ, Boon MR, Van Der Zon GC, et al. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes 2014;63:880-891.
115. Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol 2008;28:1050-1059.
116. Kirchgessner TG, Sleph P, Ostrowski J, et al. Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils. Cell Metab 2016;24:223-233.
117. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394:2184-2196.
118. Intercept announces withdrawal of EMA marketing authorization application for obeticholic acid for advanced liver fibrosis due to NASH - intercept pharmaceuticals, Inc. Available from: https://ir.interceptpharma.com/news-releases/news-release-details/intercept-announces-withdrawal-ema-marketing-authorization [Last accessed on 27 Jun 2022].
119. Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2021;19:60-78.
120. Diabetes [Internet]. Available from: https://www.who.int/health-topics/diabetes#tab=tab_1 [Last accessed on 27 Jun 2022].
121. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-1722.
122. Ridker PM, Everett BM, Thuren T, et al. CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.
123. Bouabdallaoui N, Blondeau L, Tardif JC. Lessons from COLCOT and LoDoCo2: colchicine for secondary prevention in coronary artery disease. Eur Heart J 2021;42:2800-1.
124. Opstal TSJ, Hoogeveen RM, Fiolet ATL, et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy. Circulation 2020;142:1996-8.
